Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

Evaluation of Echinacea for the Common Cold

This study has been completed.
Sponsor:
Information provided by:
National Center for Complementary and Integrative Health (NCCIH)
ClinicalTrials.gov Identifier:
NCT00032500
First received: March 22, 2002
Last updated: August 17, 2006
Last verified: July 2006
History of Changes
  Purpose

The purpose of this study is to determine whether three Echinacea preparations with different chemical compositions are effective for prevention or treatment of the common cold.


Condition Intervention Phase
Common Cold
 Drug: Echinacea
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: Evaluation of Echinacea in a Human Rhinovirus Challenge

Resource links provided by NLM:

MedlinePlus related topics: Common Cold
Drug Information available for: Echinacea
U.S. FDA Resources

Further study details as provided by National Center for Complementary and Integrative Health (NCCIH):
Study Start Date: September 2001
Estimated Study Completion Date: May 2004
Detailed Description:

Echinacea is a widely used herbal remedy for the common cold. Previous clinical trials designed to assess the efficacy of Echinacea for prevention or treatment of the common cold have produced inconsistent results. A variety of different Echinacea products have been used in these clinical trials. Recent studies indicate that different Echinacea preparations have dramatically different phytochemical profiles. The available clinical trial data provide no information about the potential role of the different constituents of Echinacea in common cold prevention or treatment. Our hypothesis is that the variation in reported clinical effectiveness may be due to differences in the phytochemical profile of the Echinacea preparations used. This study will address the following specific aims: 1) Evaluate the effectiveness of chemically defined extracts of E. angustifolia root which contain alkamides, echinacoside or polysaccharidelglycoprotein for common cold prevention or treatment; 2) Assess the correlation between specific Echinacea metabolites in serum and nasal secretions and efficacy for prevention and treatment of colds; and 3) Determine the effect of different Echinacea preparations on the host response to rhinovirus infection.

  Eligibility
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00032500

Locations
United States, Virginia
University of Virginia, Charlottesville
Charlottesville, Virginia, United States, 22904
Sponsors and Collaborators
National Center for Complementary and Integrative Health (NCCIH)
Investigators
Principal Investigator: Ronald B. Turner, MD University of Virginia School of Medicine
Investigator: J. David Gangemi, PhD Clemson University
Investigator: Rudolf Bauer, PhD Karl-Franzens-Universitaet Graz
  More Information

Publications:

ClinicalTrials.gov Identifier: NCT00032500     History of Changes
Other Study ID Numbers: R01 AT001146-01
Study First Received: March 22, 2002
Last Updated: August 17, 2006
Health Authority: United States: Federal Government

Keywords provided by National Center for Complementary and Integrative Health (NCCIH):
common cold
Echinacea

Additional relevant MeSH terms:
Common Cold
Picornaviridae Infections
RNA Virus Infections
 Respiratory Tract Diseases
Respiratory Tract Infections
Virus Diseases

ClinicalTrials.gov processed this record on March 02, 2015